ALNEV.PA stock down 14.29% intraday on EURONEXT 09 Feb 2026: market risks ahead

ALNEV.PA stock fell intraday 14.29% to €0.0024 on EURONEXT on 09 Feb 2026, making it one of the top losers in Europe’s healthcare list. Trading volume hit 9,172,848 shares, above the 3‑month average, and the session low was €0.0023. Investors reacted to continued cash strain, negative earnings metrics and thin liquidity. Below we break down the drivers, valuation, technicals and short-term outlook for Neovacs S.A. (ALNEV.PA stock) using real-time metrics and Meyka AI analysis.

Intraday price action for ALNEV.PA stock

Neovacs (ALNEV.PA) opened at €0.0026 and hit a day low of €0.0023 before the close at €0.0024. The intraday decline of -14.29% far outpaced Healthcare peers. Volume was 9,172,848, a relative volume of 1.51, signaling above‑average selling pressure. The market cap stands at €1,192.00, highlighting microcap status and outsized volatility in intraday moves.

Fundamentals and ALNEV.PA stock valuation

Neovacs reports a trailing EPS of -221.36 and no meaningful P/E. Price to book sits near 0.00002, a reflection of a tiny market cap versus reported book value per share. Revenue per share is 2.10 while net income per share is -188.61, showing persistent losses. Current ratio is 0.63, and research and development to revenue is 10.94. These metrics help explain why ALNEV.PA stock trades at a distressed valuation versus European healthcare peers.

Meyka grade and analyst context for ALNEV.PA stock

Meyka AI rates ALNEV.PA with a score of 62.03 out of 100 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. The company also carries a third‑party company rating of C- / Strong Sell dated 2025-02-28, reflecting weak profitability and cash metrics. These mixed signals frame ALNEV.PA stock as speculative for most investors.

Technicals and trading liquidity for ALNEV.PA stock

Technicals show oversold momentum: RSI 27.61, MACD histogram -0.01, and ADX 29.67, indicating a strong downtrend. Average 50‑day price is €0.0084 and 200‑day average is €1.599, underscoring long-term weakness. On‑book volume indicators are negative with OBV at -10,112,661. Low free float and tiny market cap reduce liquidity, raising execution risk for larger orders in ALNEV.PA stock.

Risks, catalysts and ALNEV.PA stock outlook

Key risks: ongoing negative EPS, limited cash runway implied by current ratio 0.63, and limited commercial revenue. Catalysts that could lift ALNEV.PA stock include positive Phase II data for IFNa Kinoid, fresh financing at acceptable terms, or a strategic partnership. Watch day‑to‑day news flow on clinical trials and financing announcements closely. For reference, the company website lists pipeline details and partnerships Neovacs.

Price support, resistance and trading strategy for ALNEV.PA stock

Near‑term support sits at the intraday low €0.0023; resistance is near the day high €0.0027 and the 50‑day average €0.0084. Suggested scenario price targets: base case €0.0012, bull case €0.0040, bear case €0.0005. Given the microcap structure and low liquidity, a risk‑management plan with tight position sizing and stop limits is prudent for ALNEV.PA stock. For raw data and company image see FinancialModelingPrep.

Final Thoughts

ALNEV.PA stock closed the intraday session on EURONEXT at €0.0024 after a -14.29% move on 09 Feb 2026. Fundamentals show persistent losses (EPS -221.36) and tight liquidity (current ratio 0.63). Meyka AI’s forecast model projects a 12‑month reference price of €0.0012, implying a downside of -50.00% versus the current price of €0.0024. Model outputs are not guarantees; they are scenario‑based projections. The Meyka grade (score 62.03/100, Grade B, HOLD) reflects mixed signals: valuable pipeline assets but weak cash flow and execution risk. Short‑term traders should treat ALNEV.PA stock as high volatility microcap. Long‑term investors need clear clinical or financing catalysts before increasing exposure. Use tight position sizing and monitor company updates and trial readouts through official channels and Meyka AI’s real‑time analysis tools.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.